A Phase II Randomized, Non-inferiority Study Comparing the Efficacy and Safety of Dalpiciclib Combined With AI With Neoadjuvant Chemotherapy in ER+ HER2- Postmenopausal Breast Cancer Patients
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 144
- 试验地点
- 1
- 主要终点
- Percentage of Participants With Complete Radiologic Response or Partial Radiological Response: Radiological Response
研究概览
简要总结
This study is a multi-center, randomized, prospective phase II clinical trial aimed at exploring and evaluating the efficacy of dalpiciclib combined with AI in neoadjuvant treatment for ER strong positive（ER≥50%），HER2-negative, Ki-67≤20%,T1-3N1M0 postmenopausal breast cancer. The primary objectives are to demonstrate non-inferiority in efficacy compared to chemotherapy and to assess its superior safety profile.
详细描述
This study is a multi-center, randomized, prospective non-inferiority exploratory phase II clinical trial. Eligible subjects were randomly assigned in a 1:1 ratio to either the dalpiciclib combined with AI group （neoadjuvant endocrine group） or the AC-T group （chemotherapy group） after screening. The administration of the investigational drugs started within 48 hours after randomization. Subjects will receive either 24 weeks of dalpiciclib combined with AI or AC-T treatment until disease progression, intolerable adverse events, withdrawal of informed consent, or discontinuation by the investigator's judgment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Sign the informed consent form to participate in the clinical research.
- •Confirmed postmenopausal females diagnosed with invasive breast cancer.
- •Clinical stage T1-3N1M
- •Pathological examination confirmed: Strong positive for ER, negative for HER
- •HER2 negative: Immunohistochemistry (IHC) suggests HER2 (-, +) or (++) but in situ hybridization (ISH) indicates negative. Strong positive for ER: ER immunohistochemistry test shows 50% or more tumor cells positive.
- •No prior breast cancer-related treatment.
- •No concurrent cardiac diseases, baseline left ventricular ejection fraction (LVEF) ≥ 50%, no significant cardiac diseases (≤ NYHA class I).
- •ECOG score of 0-1, meeting the indications and basic requirements for chemotherapy without major organ dysfunction.
- •Within 1 week prior to enrollment, routine blood tests are essentially normal: Absolute neutrophil count (NEUT#) ≥ 1.5×10^9 /L; White blood cell count (WBC) ≥ 3.0×10^9 /L; Platelets ≥ 90×10^9 /L; Hemoglobin ≥ 90 g/L.
- •Within 1 week prior to enrollment, liver and kidney function tests are essentially normal: Total bilirubin (TBIL) ≤ 1.5× upper limit of normal (ULN); Alanine aminotransferase and aspartate aminotransferase (ALT/AST) ≤ 2× ULN; Serum creatinine ≤ 1.5× ULN or creatinine clearance rate (Ccr) ≥ 60 ml/min.
- •For women of childbearing age, negative serum or urine pregnancy test results before participation; premenopausal women during the study period should use medically acceptable methods of contraception.
- •Exhibits good compliance.
排除标准
- •Pregnant or lactating women, and women of childbearing age who have a positive pregnancy test at baseline and do not agree to use effective contraception during the study.
- •Patients with a known history of severe allergic reactions to any investigational drug components (NCI-CTCAE Grade > 3) or with any clearly documented drug allergy.
- •Patients with bilateral breast cancer or inflammatory breast cancer.
- •Patients with metastatic (stage IV) breast cancer at initial diagnosis.
- •Patients with a history of congestive heart failure, unstable angina, arrhythmias, or myocardial infarction.
- •Current diagnosis of acute lung conditions, interstitial lung disease, pulmonary fibrosis, acute pulmonary disease, etc.
- •Current diagnosis of severe liver-related diseases such as acute hepatitis, fulminant hepatitis, coagulation factor synthesis disorders. If HBV surface antigen or HBV core antibody are positive, the peripheral blood HBV DNA titer should be < 1×10^3 IU/ml for eligibility.
- •Any other serious medical condition or comorbidity that may interfere with participation in the study or may significantly affect the safety of the subject (e.g., active or uncontrolled infections, active or requiring antiviral therapy for liver and bile diseases).
- •Other invasive malignancies (including second primary breast cancer) that may interfere with the evaluation of study endpoints and compliance with the protocol.
- •Patients with a history of prior treatment with chemotherapy, endocrine therapy, or anti-HER2 biologic therapy for breast cancer (excluding diagnostic biopsy for primary breast cancer).
- •Patients who have undergone major surgery within 4 weeks prior or have significant unresolved medical conditions.
- •Patients with non-measurable tumors during treatment.
- •Any other condition that the investigator deems unsuitable for the participation of the subject in the study.
研究组 & 干预措施
neoadjuvant endocrine group
Dalpiciclib: Take 125 mg once daily for 3 weeks, then stop for 1 week. Each cycle is completed in 4 weeks.
AI: Take according to the instructions provided.
干预措施: Dalpiciclib (Drug)
neoadjuvant endocrine group
Dalpiciclib: Take 125 mg once daily for 3 weeks, then stop for 1 week. Each cycle is completed in 4 weeks.
AI: Take according to the instructions provided.
干预措施: Aromatase inhibitor (Drug)
neoadjuvant chemotherapy group
Docetaxel for injection: Administered as a 75 mg/m2 intravenous infusion Epirubicin hydrochloride for injection: Administered as a 75 mg/m2 intravenous infusion.
Cyclophosphamide for injection: Administered as a 500 mg/m2 intravenous infusion.
干预措施: Docetaxel injection (Drug)
neoadjuvant chemotherapy group
Docetaxel for injection: Administered as a 75 mg/m2 intravenous infusion Epirubicin hydrochloride for injection: Administered as a 75 mg/m2 intravenous infusion.
Cyclophosphamide for injection: Administered as a 500 mg/m2 intravenous infusion.
干预措施: Epirubicin Hydrochloride Injection (Drug)
neoadjuvant chemotherapy group
Docetaxel for injection: Administered as a 75 mg/m2 intravenous infusion Epirubicin hydrochloride for injection: Administered as a 75 mg/m2 intravenous infusion.
Cyclophosphamide for injection: Administered as a 500 mg/m2 intravenous infusion.
干预措施: Cyclophosphamide injection (Drug)
结局指标
主要结局
Percentage of Participants With Complete Radiologic Response or Partial Radiological Response: Radiological Response
时间窗: 6 months
Radiological response is the percentage of participants with CR or, PR according to RECIST v.1.1. A responder is defined as any participant who exhibits a CR or PR. CR is the disappearance of all target lesions. PR is a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. PD is 20% increase in the sum of diameters of target lesions taking as reference the smallest sum and the appearance of 1 or more new lesions.
次要结局
- Evaluation of the number of patients with a Residual Cancer Burden (RCB) 0-I index(6 months)
- Calculation of the rates of breast conservation therapy in the two arms with regard to the initially planned surgery.(6 months)
- Evaluation of the number of patients with PEPI 0(6 months)
- Percent Change From Baseline to 2 Weeks in Ki67 Expression(2 Weeks)
- Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)(6 months)
- Percentage of Participants With Pathologic Complete Response (pCR)(6 months)
- Determination of the number and type of Adverse Events as a Measure of Safety and Tolerability(6 months)